Walleye Capital
MRNA icon

Walleye Capital’s Moderna MRNA Stock Holding History

Walleye Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.5M Sell
305,200
-44,000
-13% -$2.05M 0.06% 264
2025
Q4 		$10.3M Buy
349,200
+79,800
+30% +$2.17M 0.03% 634
2025
Q3 		$6.96M Sell
269,400
-40,300
-13% -$1.12M 0.03% 734
2025
Q2 		$8.54M Buy
309,700
+186,100
+151% +$4.9M 0.03% 578
2025
Q1 		$3.5M Buy
123,600
+78,800
+176% +$2.8M 0.02% 1025
2024
Q4 		$1.86M Buy
44,800
+12,400
+38% +$593K ﹤0.01% 1845
2024
Q3 		$2.17M Sell
32,400
-56,000
-63% -$5.14M ﹤0.01% 1869
2024
Q2 		$10.5M Sell
88,400
-30,400
-26% -$3.85M 0.02% 724
2024
Q1 		$12.7M Buy
118,800
+67,600
+132% +$6.81M 0.02% 686
2023
Q4 		$5.09M Buy
51,200
+4,200
+9% +$353K 0.01% 1097
2023
Q3 		$4.85M Buy
47,000
+18,900
+67% +$2.11M 0.01% 1050
2023
Q2 		$3.41M Buy
28,100
+19,300
+219% +$2.57M 0.01% 969
2023
Q1 		$1.35M Sell
8,800
-4,100
-32% -$676K 0.02% 948
2022
Q4 		$2.32M Buy
12,900
+2,500
+24% +$409K 0.04% 508
2022
Q3 		$1.23M Buy
+10,400
New +$1.58M 0.02% 831
2020
Q2 		– Sell
-24,000
Closed -$719K – 834
2020
Q1 		$719K Sell
24,000
-28,200
-54% -$649K 0.16% 171
2019
Q4 		$1.02M Buy
+52,200
New +$926K 0.07% 406

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital's MRNA Position: Q1 2026 in Review

Walleye Capital reduced its Moderna (MRNA) stake by 100% in Q1 2026, selling an estimated $8.02M and leaving 171 shares worth $8.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4168.

Walleye Capital first reported a position in MRNA in Q2 2019 and has held it in 13 quarters since. The position peaked at $8.79M in Q1 2025. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Walleye Capital held 171 shares of Moderna worth $8.69K as of Q1 2026.
  • Walleye Capital sold 171,988 Moderna shares in Q1 2026, an estimated $8.02M.
  • Moderna made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4168 holding.
  • Walleye Capital first reported a position in Moderna in Q2 2019 and has held it in 13 quarters since.
  • Walleye Capital's Moderna position peaked at $8.79M in Q1 2025.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.